[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endothelial-function-fmd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endothelial-function-fmd":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,84,119,156],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100584490","a-prospective-single-center-observational-study-aiming-to-assess-the-predictive-role-of-flow-mediated-dilatation-in-acute-coronary-syndromes-combined-with-echocardiographic-and-biochemical-indices-100584490",false,"NCT06890013","A Prospective, Single-center, Observational Study Aiming to Assess the Predictive Role of Flow Mediated Dilatation in Acute Coronary Syndromes, Combined With Echocardiographic and Biochemical Indices","Identifying the Role of Flow Mediated Dilatation Assessment in Acute Coronary Syndromes - Evaluation of the Cor-IS Technology (the FLARE-ACS Trial)","FLARE-ACS","Inclusion Criteria:\n\n1. Age \\> 18 years\n2. Patients hospitalized due to acute coronary syndrome (STEMI, NSTEMI)\n3. Capability of providing written informed consent\n4. Patients able to comply with the follow-up schedule of the study\n\nExclusion Criteria:\n\n1. Patients with acute coronary syndromes classified as MINOCA, or type II myocardial infarction\n2. Patients with rare acute coronary syndrome types, such as spontaneous coronary artery dissection or Takotsubo syndrome\n3. Patients with congenital heart disease\n4. Age \\> 85 years\n5. Patients with end stage chronic kidney disease\n6. Patients with active malignancy or autoimmune diseases which limit their survival\n7. Patients with expected survival \\\u003C 1 year due to other reasons\n8. Suboptimal echocardiographic windows\n9. Inability to provide written consent\n10. Inability to comply with the follow-up schedule of the study\n11. Pregnancy\n12. Use of intravenous drugs","ALL","18 Years","85 Years",{"count":21,"type":22},100,"ESTIMATED","OBSERVATIONAL","A prospective, single-center, observational study aiming to assess the predictive role of flow mediated dilatation in acute coronary syndromes, combined with echocardiographic and biochemical indices. The novel Cor-IS technology will also be evaluated.",[26,27,28],"Acute Coronary Syndromes","Flow Mediated Dilation","Endothelial Function (FMD)",[30,31,32,33],"acute coronary syndrome","endothelial dysfunction","biomarker","flow mediated dilatation","RECRUITING","2026-02-27",{"date":37,"type":38},"2026-03-02","ACTUAL",{"date":40,"type":38},"2024-06-01",{"date":42,"type":22},"2026-11-01",{"name":44,"class":45},"Aristotle University Of Thessaloniki","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":46},"100582654","effects-of-estrogen-on-heart-health-in-women-with-primary-ovarian-insufficiency-100582654","NCT06866119","Effects of Estrogen on Heart Health in Women With Primary Ovarian Insufficiency","Effects of Estrogen Replacement on Cardiometabolic Endpoints in Women With Primary Ovarian Insufficiency","ENCODE","Inclusion criteria (I):\n\n* female sex\n* age 30-40\n* CASE PARTICIPANTS ONLY: clinically documented POI diagnosis within 6 months\n* CASE PARTICIPANTS ONLY: planning to clinically initiate 100mcg transdermal 17beta-estradiol twice weekly and micro-ionized progesterone (either 100mg daily or 200mg cyclically)\n* CONTROL PARTICIPANTS ONLY: regular menstrual cycles every 21-35 days\n\nExclusion criteria (E):\n\n* CASE PARTICIPANTS ONLY: genetic POI etiology\n* CASE PARTICIPANTS ONLY: any prior initiation of ERT\n* systemic estrogen, progesterone or testosterone therapy within the past 6 months (including contraception, except for locally acting intrauterine devices - IUDs)\n* lipid lowering therapy within the past 6 months\n* use of antihypertensive medication within the past 6 months\n* current treatment with prescription, systemic (oral, IV, or IM) steroids or anti-inflammatory\u002Fimmune suppressant medical therapies (excluding topical therapies, UV therapy, ASA-derivative therapies, or NSAIDS) for autoimmune\u002Finflammatory diseases (psoriasis, RA, IBD, lupus), post-transplant care, asthma, or pain syndromes\n* use of oral steroids or prescription oral anti-inflammatory\u002Fimmune suppressant medication for \\>7 days within the past 1 month\n* use of IV or IM steroids or IV or IM anti-inflammatory\u002Fimmune suppressant medication within the past 3 months\n* self-reported history of breast and\u002For estrogen dependent malignancy\n* self-reported history of deep vein thromboembolism, pulmonary embolism or stroke\n* self-reported severe liver disease such as cirrhosis\n* self-reported hypercoagulable disorder\n* uncontrolled hypertension at baseline Visit #1- systolic blood pressure (SBP) ≥180 and\u002For diastolic blood pressure (DBP) ≥110\n* tobacco use within 6 months\n* self-reported history of myocardial infarction, stroke, coronary revascularization or diabetes as a CVD risk equivalent\n* stable or unstable angina\n* self-reported history of heart failure\n* pregnancy or breastfeeding\n* concurrent enrollment in conflicting research study",true,"FEMALE","30 Years","40 Years",{"count":60,"type":22},45,"The goal of this observational study is to study the effects of treating women with Primary Ovarian Insufficiency (POI) with estrogen replacement therapy to bolster the evidence backing cardiometabolic preventive care in women with POI. The main question it aims to answer is:\n\nDoes 6 months of estrogen replacement therapy for women with POI improved markers of heart health?\n\nWomen newly diagnosed with POI (within 6 months) who are planning to start estrogen replacement therapy from their clinical provider will undergo assessment of markers of heart health before and after 6 months of treatment. These markers will also be compared to those obtained from healthy women without POI.",[63,64,65,28,66],"Primary Ovarian Insufficiency","Premature Menopause","Metabolic Complications","Estrogen Replacement Therapy",[68,69,70,71,72,73],"primary ovarian insufficiency","premature menopause","estrogen replacement therapy","cardiovascular disease prevention","POI","ERT","NOT_YET_RECRUITING","2026-01-05",{"date":77,"type":38},"2026-01-07",{"date":79,"type":22},"2026-03-01",{"date":81,"type":22},"2026-06",{"name":83,"class":45},"Massachusetts General Hospital",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":104,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":46},"100611763","probing-the-role-of-mitochondrial-oxidative-stress-in-impaired-vascular-function-among-young-adults-with-early-life-adversity-100611763","NCT07244809","Probing the Role of Mitochondrial Oxidative Stress in Impaired Vascular Function Among Young Adults With Early Life Adversity","PROMISE","Inclusion Criteria:\n\n* 18-29 years\n* ACE score \\>=4\n\nExclusion Criteria:\n\n* Resting arterial blood pressure \\>140\u002F90 mmHg\n* BMI \\\u003C=17 or \\>= 35\n* Are on a weight-loss diet or involved in a formal weight-loss program or are not intentionally weight stable for 6 months (+\u002F- 5 kg) prior to the study.\n* Cardiovascular or metabolic prescription drug use\n* Vasoactive antidepressant drug use (SSRIs and clonidine)\n* Current heavy alcohol use, as defined as binge drinking on 5 or more days in the last month, or consuming more than 7 (women) or 14 (men) drinks per week in the last month (per NIAAA definition)\n* Current or recent (within the last 6 mo.) illicit drug use disorder as indicated by a score of 3 or greater on the Drug Abuse Screening Test (DAST-10)\n* Current tobacco or nicotine use\n* Vaping\n* Regular vigorous (\\>6 METs) aerobic exercise (\\>4 bouts\u002Fweek, \\>30 min\u002Fbout)\n* dietary supplementation with antioxidants or habitual use of NSAIDs\n* Currently pregnant or breastfeeding","29 Years",{"count":93,"type":22},300,"INTERVENTIONAL",[96],"NA","Adverse childhood experiences (ACEs) represent highly stressful events in the first 18 years of life that include abuse, neglect, and household and community-level dysfunction. Greater exposure to ACEs are associated with greater increases in the risk of cardiovascular diseases and death. Our laboratory has previously observed that vascular function is disrupted in young adults with prior ACE exposure, even though these individuals appear to be healthy clinically (i.e., no classic clinical cardiovascular disease risk factors). There is a need to identify and understand the biological mechanisms underlying these vascular impairments to inform effective interventions to reduce cardiovascular risks the millions of individuals affected by ACEs.\n\nThe body's response to stress is coordinated across various systems, all of which depend on energy supplied by mitochondria (often referred to as the \"powerhouse of cells\"). Based on new evidence across multiple physiological systems from our team, our overarching hypothesis is that disruption of mitochondrial function contributes to cardiovascular impairments among young adults with ACEs. Here we propose the initial pilot work necessary to begin to understand these associations, which will directly inform identification of individuals who may be most vulnerable to stress-related cardiovascular risk and the development of interventions to promote cardiovascular-stress resilience.\n\nOur aims are to:\n\n1. Determine whether mitochondrial oxidative stress contributes to impaired vascular function among young adults who experienced early life adversity.\n2. Determine whether reducing mitochondrial oxidative stress improves the cellular stress and integrated cardiovascular response to laboratory-based psychosocial stress among young adults who experienced early life adversity.",[99,28,100,101,102,103],"Adverse Childhood Experience","Endothelial Injury","Mitochondrial Function","Oxidative Stress","Psychosocial Influence on Cardiovascular Disease",[105,106,107,108,109],"flow mediated dilation","mitoquinone mesylate","placebo","early life adversity","trier social stress test","2025-11-17",{"date":112,"type":38},"2025-11-24",{"date":114,"type":38},"2025-10-13",{"date":116,"type":22},"2026-12-31",{"name":118,"class":45},"University of Iowa",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":94,"phases":127,"briefSummary":129,"conditions":130,"keywords":135,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":46},"100611783","phase-2-use-of-dapagliflozin-in-primary-prevention-of-cardiotoxicity-of-anthracycline-chemotherapy-in-breast-cancer-patients-100611783","NCT07245069","Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients","Alpaca","Inclusion Criteria:\n\n* Adults ≥18 years.\n* Histologically confirmed breast cancer with planned (neo)adjuvant anthracycline-based chemotherapy (4 cycles of epirubicin + cyclophosphamide or doxorubicin + cyclophosphamide).\n* Eligible to start dapagliflozin or placebo prior to or at initiation of chemotherapy.\n* Able to perform baseline echocardiography, vascular ultrasound (FMD and carotid stiffness), 6-minute walk test, and biomarker sampling.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Known heart failure (any prior diagnosis of HF).\n* Clinically significant valvular heart disease.\n* Prior exposure to chemotherapy or radiotherapy to the left chest.\n* Type 1 diabetes mellitus.\n* Symptomatic hypotension.\n* History of recurrent urinary tract infections.\n* History of diabetic ketoacidosis or ketonemia.\n* Severe hepatic impairment (ALT, AST, ALP \\>3× upper limit of normal).\n* Severe renal impairment (eGFR \\\u003C20 mL\u002Fmin\u002F1.73 m²).\n* Known allergy or intolerance to SGLT-2 inhibitors.\n* Any use of SGLT-2 inhibitor therapy within 3 months prior to enrollment.\n* Pregnancy or breastfeeding.\n* Any condition that, in the investigator's judgment, could interfere with study participation, safety, or completion.",{"count":21,"type":22},[128],"PHASE2","The goal of this randomized, double-blind, placebo-controlled clinical trial is to determine whether dapagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, can help prevent anthracycline-induced cardiotoxicity caused by anthracycline chemotherapy in adult women with breast cancer receiving (neo)adjuvant treatment.\n\nThe main questions the study aims to answer are:\n\ni) Does dapagliflozin reduce the decline in left ventricular function (measured by LVEF, GLS, and myocardial work) during and after anthracycline therapy? ii) Does dapagliflozin lessen the deteriorating effect of chemotherapy on endothelial function and arterial stiffness? iii) Does dapagliflozin effect levels of cardiac injury and inflammation biomarkers (e.g., hs-troponin T, NT-proBNP, ST-2, GDF-15, galectin-3, IL-6, MPO)?\n\nResearchers will compare dapagliflozin 10 mg daily with placebo to see whether those receiving dapagliflozin experience less heart and vascular impairment during treatment.\n\nParticipants will:\n\n* Take either dapagliflozin or placebo once daily during anthracycline chemotherapy.\n* Undergo heart and vascular ultrasound, and a 6-minute walk test before chemotherapy and again at 24 and 52 weeks.\n* Provide blood samples before, during and after chemotherapy to measure cardiac biomarkers.\n* Complete multiple questionnaires on quality of life.",[131,132,28,133,134],"Heart Failure","Anthracycline-induced Cardiac Toxicity","Arterial Stiffness","Breast Cancer",[136,137,134,138,139,140,141,142,143,144,145,146,131,147,148],"Anthracycline-induced cardiac toxicity","Dapagliflozin","Cardio-Oncology","Primary Prevention","Global Longitudinal Strain","Myocardial Work","Endothelial Function","Flow-Mediated Dilation","Pulse Wave Velocity","Troponin","NT-proBNP","Inflammation","Sodium-Glucose Transporter 2 Inhibitors",{"date":112,"type":38},{"date":151,"type":38},"2025-02-01",{"date":153,"type":22},"2029-02",{"name":155,"class":45},"University Medical Centre Ljubljana",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":55,"sex":56,"minAge":18,"maxAge":58,"enrollmentInfo":164,"targetDuration":4,"studyType":94,"phases":166,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":46},"100599456","identifying-biomarkers-for-endothelial-dysfunction-in-women-with-preeclampsia-100599456","NCT07084727","Identifying Biomarkers for Endothelial Dysfunction in Women With Preeclampsia","Retinal Biomarkers as a Tool for Early Detection of Endothelial Dysfunction in Women With Preeclampsia","DAISY","Inclusion Criteria:\n\n* at least 18 years old\n* willing to undergo vascular assessments\n* informed consent signed\n\nExclusion Criteria:\n\n* Unwilling to provide informed consent\n* Open-angle glaucoma\n* Epilepsia\n* (gestational) Diabetes\n* Multiple pregnancies\n* Fetal malformations\n* Hypercholesterolemia\n* Kidney disease\n* Auto-immune disorders\n* Connective tissue diseases",{"count":165,"type":22},60,[96],"Every pregnancy has a major impact on a woman's heart and blood vessels due to changes required by the body to maintain proper blood flow between mother and foetus. When the placenta does not work properly, preeclampsia can occur. An important first symptom is high blood pressure. Women who have experienced preeclampsia are at higher risk of developing blood pressure and heart problems later on. Therefore, it is very important to detect changes in the blood vessel system so that they can be treated promptly and correctly. We aim to do this by using a new, non-invasive eye test that examines the blood vessels of the retina.",[28,169,170],"Preeclampsia","Retinal Vessels","2025-07-17",{"date":173,"type":38},"2025-07-24",{"date":175,"type":38},"2025-07-01",{"date":177,"type":22},"2025-12-15",{"name":179,"class":45},"University Hospital, Antwerp"]